NuVasive | Les Charges D'Exploitation



Les Charges D'Exploitation Changement Date
Abbott USD 9.21B 17M 2025-12
AtriCure USD 138.01M 3.95M 2025-12
Baxter International USD 3.19B 554.4M 2025-12
Becton, Dickinson and Co. USD 4.59B 476M 2025-12
Boston Scientific USD 4.04B 18M 2025-12
Cooper Companies USD 924.8M 40.2M 2025-09
Dexcom USD 936.6M 30.2M 2025-12
Edwards Lifesciences USD 1.2B 71.3M 2025-12
Globus Medical USD 645.11M 241.46M 2025-12
Haemonetics USD 134.99M 1.26M 2025-12
Hologic USD 349.4M 447.1M 2025-12
Inogen USD 49.14M 665K 2024-09
Insulet USD 637.5M 48.9M 2025-12
Integra LifeSciences USD 368.92M 668.65M 2025-12
Intuitive Surgical USD 2B 263.6M 2025-12
J&J USD 18.97B 2.38B 2025-12
Medtronic USD 7.28B 16M 2025-12
Merit Medical Systems USD 339.74M 1.8M 2025-12
Orthofix International USD 10.89M 209.57M 2024-09
Stryker USD 5.2B 505M 2025-12
Tandem Diabetes Care USD 282.09M 9.97M 2025-12
Teleflex USD 532.64M 3.29B 2025-12
Zimmer Biomet Holdings USD 1.94B 277.8M 2025-12


NuVasive Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2026.